Affymax Drug Promising for Dialysis Anemia

[okarol]

Affymax Drug Promising for Dialysis Anemia

U.S. firm Affymax said Thursday results from its phase 2 study of Hematide appears effective in treating anemia in dialysis patients.

The company said its open-label, maintenance-switch trial showed 165 patients who had been taking Epoetin Alfa three times a week, and switched to monthly doses of Hematide were able to maintain mean hemoglobin at clinically acceptable levels.

The study results are especially important given the growing concerns related to excessive hemoglobin increases due to erythropoiesis stimulating agent use, said Anatole Besarab, adjunct professor of medicine at Wayne State University and director of clinical research at Henry Ford Hospital in Detroit, Mich., in a statement issued by the company.

Affymax presented the data at the National Kidney Foundation 2007 Spring Clinical Meeting in Orlando, Fla.

http://www.redorbit.com/news/health/900138/affymax_drug_promising_for_dialysis_anemia/index.html?source=r_health#